trials eric siemers alzheimer researcher lilly optimistic surprising solanezumab worked says lot promise slow progression lilly launched larger phase iii trial solanezumab 2013 enrolling 2,100 people mild symptoms amyloid deposits brains company end study october 2016 december biogen said launch phase iii trial 2,700 participants run 18 months lon schneider alzheimer researcher university southern california los angeles questions decision start large trials drugs amyloid hypothesis validated antibodies far proven efficacy says noting behavioral interventions diet exercise shown slow alzheimer drug not agrees time bold says randall bateman neurologist washington university st. louis missouri cost delay human suffering standpoint expensive cost